Literature DB >> 8125131

Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo.

V Flamand1, T Sornasse, K Thielemans, C Demanet, M Bakkus, H Bazin, F Tielemans, O Leo, J Urbain, M Moser.   

Abstract

The aim of this work is to induce tumor resistance to a B cell lymphoma in BALB/c mice using elements of the immune system. It has indeed been shown by us and by others that antigen-presenting cells (APC) like dendritic cells can induce efficient immune responses and can even substitute for Freund's adjuvant. Here we show that mice immunized with syngeneic dendritic cells pulsed in vitro with tumor antigen (BCL1 idiotype expressed by lymphoma cells) are protected against a subsequent tumor inoculation. The in vivo resistance can be correlated with the induction of a humoral response specific for the idiotype expressed by the tumor. No such protection can be achieved when B cells are used as APC. These data show that effector cells in tumor-bearing animals can be recruited and activated using dendritic cells, providing long-lasting immune surveillance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8125131     DOI: 10.1002/eji.1830240317

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  47 in total

1.  Cellular but not humoral immune responses generated by vaccination with dendritic cells protect mice against leukaemia.

Authors:  B M Colombo; R Lacave; C Pioche-Durieu; C Masurier; F M Lemoine; M Guigon; D Klatzmann
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Spontaneous proliferation and type 2 cytokine secretion by CD4+T cells in patients with metastatic melanoma vaccinated with antigen-pulsed dendritic cells.

Authors:  A Karolina Palucka; John Connolly; Hideki Ueno; John Kohl; Sophie Paczesny; Madhav Dhodapkar; Joseph Fay; Jacques Banchereau
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

3.  Dendritic cells efficiently induce protective antiviral immunity.

Authors:  B Ludewig; S Ehl; U Karrer; B Odermatt; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells.

Authors:  J Gong; D Chen; M Kashiwaba; Y Li; L Chen; H Takeuchi; H Qu; G J Rowse; S J Gendler; D Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Antigen presentation in retroviral vector-mediated gene transfer in vivo.

Authors:  E S Song; V Lee; C D Surh; A Lynn; D Brumm; D J Jolly; J F Warner; S Chada
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 6.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 7.  The development of dendritic cell vaccine-based immunotherapies for glioblastoma.

Authors:  David A Reardon; Duane A Mitchell
Journal:  Semin Immunopathol       Date:  2017-01-30       Impact factor: 9.623

Review 8.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

Review 9.  Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.

Authors:  Catherine E Handy; Emmanuel S Antonarakis
Journal:  Future Oncol       Date:  2017-12-20       Impact factor: 3.404

Review 10.  A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.